

# **U.S. Government Positions on Decision Points from the Thirty-Sixth Board Meeting of the Global Fund**



# **PEPFAR**

**U.S. President's Emergency Plan for AIDS Relief**

The Administration provides this report pursuant to Section 202(d)(6) of the United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003, as amended, which requires that “following each meeting of the Board of the Global Fund, the Coordinator of United States Government Activities to Combat HIV/AIDS Globally shall report on the public website of the Coordinator a summary of Board decisions and how the United States Government voted and its positions on such decisions.”

## **Overview**

The Global Fund to Fight AIDS, Tuberculosis (TB) and Malaria (Global Fund) held its 36th Board Meeting on November 16-17, 2016 in Montreux, Switzerland. The Board approved \$11.1 billion USD for the upcoming 3-year allocation period for country investments, mobilizing resources from the successful Fifth Replenishment. Board Members discussed a number of additional issues including the use of \$800 million USD for “catalytic” investments, the process for the appointment of a new Executive Director, and the need for further evaluation of the Fund’s Key Performance Indicator targets.

The Global Fund is a unique financing mechanism that relies on partnerships among governments; civil society - including community and faith-based organizations; international organizations; bilateral and multilateral donors; the private sector; and affected communities in the fight against HIV/AIDS, TB, and malaria. The U.S. Government’s contributions to and engagement with the Global Fund are a central element of its strategy for achieving success in the fight against HIV/AIDS, TB, and malaria.

The U.S. government remains the largest bilateral donor to the Global Fund. Global Fund investments have provided HIV/AIDS treatment for 9.2 million people, TB testing and treatment for 15.1 million people, and distributed 659 million insecticide-treated bed nets for malaria prevention contributing to 60 % decrease in malaria deaths.

At the 36th Board Meeting, the U.S. government was represented by an interagency delegation led by Board Member Ambassador Deborah Birx, U.S. Global AIDS Coordinator and Special Representative for Global Health Diplomacy; Alternate Board Member, Ambassador Jimmy Kolker, Assistant Secretary for Global Affairs, Department of Health and Human Services; and Admiral Tim Ziemer, Coordinator of the President’s Malaria Initiative, who was the senior representative from USAID. Michael Ruffner and Sandra Thurman represent the U.S. government on the Board’s committees.

All decisions taken at the meeting are available online at:  
<http://www.theglobalfund.org/en/board/meetings/36/>

All U.S. Government positions are summarized below.

### **U.S. Government Positions on Board Decision Points**

#### ***Appointment of Rapporteur (GF/B36/DP01)***

The U.S. Government supported this decision point, which designated Carsten Staur from the Point Seven constituency as Rapporteur for the 36<sup>th</sup> Board Meeting.

#### ***Approval of Agenda (GF/B36/DP02)***

The U.S. Government supported this decision point.

#### ***Continuing Resource Mobilization Efforts Throughout the Replenishment Cycle (GF/B36/DP03)***

The U.S. Government supported this decision point.

#### ***Approval of the Amended and Restated Comprehensive Funding Policy (GF/B36/DP04)***

The U.S. Government supported this decision point, which addressed concerns over the procedures used by the Global Fund to calculate sources of funds for allocation periods.

#### ***Sources and Uses of Funds for the 2017 – 2019 Allocation Period (GF/B36/DP05)***

The U.S. Government supported this decision point. The total amount of funding was US \$11.1 billion for the 3 year allocation for country investments, including US \$10.3 billion for grant making in approximately 124 countries.

#### ***Catalytic Investments for the 2017 – 2019 Allocation Period (GF/B36/DP06)***

The U.S. Government supported this decision point, which totaled US \$800 million. Those investments provide additional support to countries to promote the aims of the Fund's 2017-2022 Strategy. PEPFAR received assurances from the Global Fund Secretariat that countries will not be capped for treatment scale-up, as was the case during the last Allocation Period.

***Executive Director Selection Process (GF/B36/DP07)***

Although the U.S. government did support the Board's decision on timelines and process for the selection of the next Executive Director, the U.S. government did not support the terms of reference for the recruitment of new Executive Director, noting the importance not only of expertise in management and leadership but also of competency in global health and in the three diseases in the term of reference.

***Corporate Work Plan and Budget Narrative 2017 and the 2017 Operating Expenses Budget (GF/B36/DP08)***

The U.S. Government supported this decision point.

***Performance Targets for the 2017 – 2022 Strategic Key Performance Indicator Framework (GF/B36/DP09)***

The decision point was not advanced at the board meeting. A working group operating under a short time frame is to review targets, modeling, and assumptions.

***Location of the 37th Board Meeting (GF/B36/DP10)***

The U.S. Government supported this decision point to hold the 37th meeting on May 3-4, 2017, in Kigali, Rwanda.